American Century Companies Inc. Has $13.85 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

American Century Companies Inc. cut its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.

3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 415,865 shares of the biotechnology company’s stock after selling 47,750 shares during the quarter. American Century Companies Inc.



owned 0.15% of Exelixis worth $13,848,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also recently modified their holdings of the company.

FMR LLC increased its position in Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after buying an additional 140,568 shares in the last quarter.

Los Angeles Capital Management LLC increased its holdings in shares of Exelixis by 20.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock valued at $71,828,000 after acquiring an additional 366,141 shares in the last quarter.

Two Sigma Advisers LP raised its position in shares of Exelixis by 6.1% during the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock worth $44,182,000 after purchasing an additional 98,000 shares during the period.

Allspring Global Investments Holdings LLC lifted its holdings in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after purchasing an additional 704,786 shares in the last quarter.

Finally, Systematic Financial Management LP grew its position in Exelixis by 7.1% in the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock valued at $30,320,000 after purchasing an additional 77,599 shares during the period.

85.27% of the stock is currently owned by institutional investors. Exelixis Stock Down 1.

4 %Shares of NASDAQ:EXEL opened at $36.39 on Wednesday. The firm has a market capitalization of $10.

18 billion, a PE ratio of 20.56, a P/E/G ratio of 1.13 and a beta of 0.

57. The company has a 50-day moving average price of $35.72 and a two-hundred day moving average price of $33.

46. Exelixis, Inc. has a twelve month low of $20.

14 and a twelve month high of $40.02. Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings data on Tuesday, February 11th.

The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.

03). Exelixis had a return on equity of 23.52% and a net margin of 24.

04%. Analysts anticipate that Exelixis, Inc. will post 2.

04 earnings per share for the current fiscal year. Insider Activity at ExelixisIn other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction dated Friday, February 14th.

The stock was sold at an average price of $34.88, for a total value of $425,884.80.

Following the sale, the director now owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.

65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Patrick J.

Haley sold 52,636 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.

28. Following the transaction, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at $11,216,403.80.

The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here.

In the last three months, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by company insiders.

Analyst Ratings ChangesA number of research analysts have weighed in on EXEL shares. Citigroup raised their price objective on shares of Exelixis from $38.00 to $45.

00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Wells Fargo & Company downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target for the company.

in a research note on Monday, February 24th. BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and increased their price objective for the stock from $36.00 to $40.

00 in a research note on Friday, December 20th. Piper Sandler lifted their target price on Exelixis from $37.00 to $38.

00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $30.00 to $40.

00 in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.

59.Check Out Our Latest Report on ExelixisExelixis Company Profile (Free Report)Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Featured ArticlesFive stocks we like better than ExelixisWhat Are Treasury Bonds?D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyStock Splits, Do They Really Impact Investors?Amazon Falls Back to a Key Support Line: Here’s How to Play ItFinancial Services Stocks InvestingBuffett Trims Equities, But Still Keeps Buying This Stock Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).

.